BioCentury
ARTICLE | Product Development

Phase III COVID-19 vaccine data kick-start next phase: mapping efficacy to antibody levels  

Though correlates of protection are still a long way off, the first Phase III data from COVID-19 vaccines launch the process to tie efficacy to antibody titers and T cell responses

November 20, 2020 11:09 PM UTC

Efficacy data from the first two Phase III trials of COVID-19 vaccines shattered expectations and validated mRNA as a vaccine modality. The findings also mark the start of the search for correlates of protection.

An analysis of the efficacy results in the context of the vaccines’ immunogenicity in early clinical trials provides the first clues to the humoral and cellular responses needed to protect the population from SARS-CoV-2. ...